SCHEMBL5165443

SCHEMBL5165443

COC(=O)C(C)N1C(=O)C=CC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.41
RAB9A P51151 4/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 1/20 0.39
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
NPC1 O15118 3/20 0.37
HPGD P15428 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
BLM P54132 1/20 0.37
WRN Q14191 1/20 0.37
HIF1A Q16665 1/20 0.37
PHGDH O43175 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
KMT2A Q03164 3/20 0.35
HTT P42858 2/20 0.35
HSP90AA1 P07900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001374 0.85 ALDH1A1 (0.42) ALDH1A1LMNAHPGDCYP1A2CYP2C19
SCHEMBL15394244 0.82 ALDH1A1 (0.40) ALDH1A1LMNAHPGDCYP1A2CYP2C19
SCHEMBL6032785 0.82 ALDH1A1 (0.36) ALDH1A1LMNAHPGDCYP1A2CYP2C19
SCHEMBL5165332 0.80 GSK3A (0.50) ALDH1A1LMNANPC1HPGDCYP1A2
SCHEMBL3874765 0.79 ALDH1A1 (0.55) RECQLRAB9AALDH1A1LMNAHPGD
SCHEMBL14868134 0.79 ALDH1A1 (0.38) RAB9AALDH1A1LMNAESR1NPC1
SCHEMBL5160610 0.77 LMNA (0.42) ALDH1A1LMNAESR1HPGDCYP1A2
SCHEMBL14868135 0.77 ALDH1A1 (0.37) RAB9AALDH1A1LMNAESR1NPC1
SCHEMBL14868136 0.77 ALDH1A1 (0.37) RAB9AALDH1A1LMNAESR1NPC1
SCHEMBL14868142 0.77 ALDH1A1 (0.37) RAB9AALDH1A1LMNAESR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1125448-A 14-substituted marcfortines and derivatives useful as antiparasitic agents UPJOHN CO (US) 1996-06-26 CN claimed
EP-2669342-B1 ACTIVE-ENERGY-RAY-CURABLE INKJET INK COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE INKJET INK, AND INKJET RECORDING METHOD KONICA MINOLTA INC (JP) 2020-03-18 EP disclosed
EP-1582548-B1 PROCESS FOR PRODUCING POLYMERIZABLE POLYBRANCHED POLYESTER DAINIPPON INK & CHEMICALS (JP) 2007-03-28 EP disclosed
US-7141642-B2 Process for producing polymerizable polybranched polyester DAINIPPON INK AND CHEMICALS, INC. (JP) 2006-11-28 US disclosed
US-20060047140-A1 Process for producing polymerizable polybranched polyester DAINIPPON INK AND CHEMICALS, INC. (JP) 2006-03-02 US disclosed
EP-1582548-A1 PROCESS FOR PRODUCING POLYMERIZABLE POLYBRANCHED POLYESTER DAINIPPON INK AND CHEMICALS, INC. (JP) 2005-10-05 EP disclosed
CN-1125448-A 14-substituted marcfortines and derivatives useful as antiparasitic agents UPJOHN CO (US) 1996-06-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060047140-A1 Process for producing polymerizable polybranched polyester ACSL4, ACSL1, HACL2 RECQL 4080/4885RAB9A 4554/4885ALDH1A1 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.